標題: |
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors 索凡替尼聯合替雷利珠單抗治療晚期實體瘤患者的開放標簽的Ib/II期臨床研究 |
主要作者: | Arvind Dasari, MD, MS, MD Anderson Cancer Center |
會議環節: | 海報展示︰發展療法 – 免疫療法 |
摘要編號: | TPS2677 |